Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · IEX Real-Time Price · USD
2.210
-0.270 (-10.89%)
At close: Mar 4, 2024, 4:00 PM
2.220
+0.010 (0.45%)
After-hours: Mar 4, 2024, 7:07 PM EST
-10.89%
Market Cap 605.18M
Revenue (ttm) 531,000
Net Income (ttm) -157.86M
Shares Out 244.93M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,623,699
Open 2.500
Previous Close 2.480
Day's Range 2.190 - 2.560
52-Week Range 0.920 - 3.790
Beta 1.28
Analysts Buy
Price Target 5.50 (+148.87%)
Earnings Date Apr 30, 2024

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collabor... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 135
Stock Exchange NASDAQ
Ticker Symbol LXRX
Full Company Profile

Financial Performance

In 2022, LXRX's revenue was $139,000, a decrease of -53.36% compared to the previous year's $298,000. Losses were -$101.94 million, 16.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 148.87% from the latest price.

Price Target
$5.5
(148.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place Ja...

2 months ago - GlobeNewsWire

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...

3 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - ...

3 months ago - GlobeNewsWire

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately i...

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place Novemb...

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA ® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology communit...

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023

THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the m...

4 months ago - GlobeNewsWire

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation

4 months ago - GlobeNewsWire

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023

4 months ago - GlobeNewsWire

Lexicon Strengthens Management Team With Two New Executives

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon P...

4 months ago - GlobeNewsWire

New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin

4 months ago - GlobeNewsWire

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP)

4 months ago - GlobeNewsWire

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Studies address cost-effectiveness and budget impact of INPEFA,  an inhibitor of SGLT2 and SGLT1

5 months ago - GlobeNewsWire

INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients

INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE W...

5 months ago - GlobeNewsWire

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

Mr. Garner brings over 25 years of pharmaceutical industry experience Mr. Garner brings over 25 years of pharmaceutical industry experience

5 months ago - GlobeNewsWire

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure

5 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference

THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Confe...

6 months ago - GlobeNewsWire

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development

6 months ago - GlobeNewsWire

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its re...

7 months ago - GlobeNewsWire

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure

7 months ago - GlobeNewsWire

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure

7 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the mark...

7 months ago - GlobeNewsWire

Lexicon Elects Diane E. Sullivan to Board of Directors

Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors Ms. Sullivan brings her extensive commercialization, strategy, and market ...

7 months ago - GlobeNewsWire

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies

9 months ago - GlobeNewsWire

UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes

9 months ago - GlobeNewsWire